Full Text
Cost-Effectiveness of Solifenacin for The Treatment of Overactive Bladder From A Us Private Payer and Medicare Advantage Perspective

Abstract

Authors

DB Ng R Wielage TM Klein RW Klein K Gooch

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×